Quick Summary
- Groundbreaking Phase 3 Success for Young Patients: EBGLYSS (lebrikizumab), a selective IL-13 inhibitor, delivered positive Phase 3 results in the ADorable-1 trial for children aged 6 months to 18 years with moderate-to-severe atopic dermatitis, achieving 63% meaningful skin improvement (EASI-75) and 44% clear/almost clear skin versus just 22% and 15% with placebo.
- Exceptional Safety & Quality of Life Improvements: The medication demonstrated excellent tolerability with no new safety concerns, zero injection site pain reported, and 35% of patients experiencing significant itch relief (≥4-point improvement). Safety profile was consistent with adult studies, making it safe across all pediatric age groups.
Eli Lilly declared that EBGLYSS (lebrikizumab-lbkz) has achieved a groundbreaking milestone in dermatology with remarkable Phase 3 results demonstrating its effectiveness in treating pediatric patients with moderate-to-severe atopic dermatitis. The positive outcomes from the ADorable-1 trial represent a significant advancement in the treatment landscape for children aged six months to 18 years suffering from this chronic inflammatory skin condition.
Key Phase 3 Results at Week 16
- 63% of patients achieved meaningful skin improvement (EASI-75) with EBGLYSS.
- 44% achieved clear or almost clear skin (IGA 0,1) compared to just 15% with placebo.
- 39% achieved near-complete skin clearance (EASI-90) through IL-13 inhibition.
- 35% experienced significant itch relief (Pruritus NRS ≥4-point improvement).
- No injection site pain was reported in any pediatric patients.
Understanding EBGLYSS: A Selective IL-13 Inhibitor Breakthrough
EBGLYSS represents a paradigm shift in atopic dermatitis treatment through its selective targeting of IL-13 signaling. This monoclonal antibody selectively blocks IL-13, a primary cytokine implicated in the inflammatory cascade that drives atopic dermatitis in both children and adults. By targeting IL-13 with high binding affinity and a slow dissociation rate, EBGLYSS prevents the formation of the IL-13Rα1/IL-4Rα receptor complex, effectively interrupting the type-2 inflammatory cycle in the skin.
The mechanism of action is particularly important for pediatric patients because IL-13 is a primary driver of skin barrier dysfunction, itch, skin thickening, and secondary infections in children with moderate-to-severe atopic dermatitis. Unlike broader immunosuppressants, this selective IL-13 inhibitor approach allows for more targeted therapy with potentially fewer systemic effects.
The ADorable-1 Trial: Rigorous Pediatric Assessment of EBGLYSS
Study Design and Patient Population
The Phase 3 ADorable-1 study (NCT05559359) was a randomized, double-blind, placebo-controlled trial that included 363 pediatric patients with moderate-to-severe atopic dermatitis. This landmark study represented the first comprehensive evaluation of an IL-13 inhibitor in children as young as six months, addressing a critical gap in treatment options for the youngest patients.
Participants received either a placebo or weight-based dosing of EBGLYSS. The trial protocol required topical corticosteroids beginning two weeks before randomization and throughout the 16-week study period, with the option to discontinue or reduce these medications once patients achieved IGA 2 or less. This design reflects real-world clinical practice while isolating the effects of EBGLYSS.
Primary and Secondary Endpoints
The study was designed with two co-primary endpoints measuring EBGLYSS effectiveness:
- EASI-75: A 75% reduction in the Eczema Area and Severity Index from baseline.
- IGA 0,1: Achievement of clear or almost clear skin (Investigator’s Global Assessment 0 or 1).
Key secondary endpoints included even greater improvements:
- EASI-90: A 90% reduction in eczema severity.
- Pruritus NRS: Four-point or greater improvement in itch severity on the Numeric Rating Scale.
Impressive Phase 3 Efficacy Data: EBGLYSS Performance vs. Placebo
| Clinical Outcome | EBGLYSS Results | Placebo Results | Difference |
|---|---|---|---|
| EASI-75 (Meaningful Improvement) | 63% | 22% | +41% |
| IGA 0,1 (Clear/Almost Clear) | 44% | 15% | +29% |
| EASI-90 (Near-Complete Clearance) | 39% | 11% | +28% |
| Pruritus NRS ≥4-point Improvement | 35% | 6% | +29% |
Safety Profile: Why EBGLYSS is Well-Tolerated in Pediatric Patients
Consistent Safety Across Age Groups
The safety profile of EBGLYSS in pediatric patients demonstrated consistency with that observed in adult and adolescent studies, with no new safety signals identified. This consistency is crucial for pediatric medications, as it suggests the IL-13 inhibitor mechanism is fundamentally safe across different age groups.
The most common adverse events occurring in 5% or more of participants were:
- Upper respiratory tract infections
- Nasopharyngitis
Notably, there was no numerical imbalance between EBGLYSS and placebo groups for these infections, suggesting they were not directly related to the medication.
Injection Site Tolerability
A significant finding was that injection site reactions were reported similarly between EBGLYSS and placebo treatment arms, with zero cases of injection site pain reported in any pediatric patients. This is particularly important for families administering injections to young children, addressing a common concern with biologic therapies.
Clinical Significance: Why These EBGLYSS Results Matter
Atopic dermatitis affects millions of children, with approximately 9.6 million children in the United States suffering from this condition. One-third of affected children have moderate-to-severe disease requiring systemic treatment. Until now, pediatric patients, especially younger children, have had fewer approved treatment options compared to adults.
Children with moderate-to-severe atopic dermatitis often endure relentless skin flares, itch and discomfort that can disrupt play, school and daily life for patients and caregivers. EBGLYSS has already changed what’s possible for adults and adolescents, delivering durable results that help patients flare less with the option of monthly maintenance dosing. Now, these data show EBGLYSS also provided disease control in pediatric patients, a critical milestone that, if approved, could bring profound relief to these patients and their families.
Adrienne Brown, Executive Vice President and President, Lilly Immunology
Impact on Pediatric Dermatology Practice
The Phase 3 results establish EBGLYSS as a selective IL-13 inhibitor option that can meaningfully improve outcomes for children with moderate-to-severe atopic dermatitis who have an inadequate response to topical therapies. The achievement of near-complete skin clearance in nearly 40% of pediatric patients represents unprecedented efficacy in this population.
Regulatory Path and Future EBGLYSS Development
Anticipated Label Expansion
Based on the positive Phase 3 results from ADorable-1, Eli Lilly plans to submit these data to U.S. and global regulatory agencies for a potential label expansion of EBGLYSS to include pediatric patients aged six months to 18 years. This regulatory pathway could significantly expand access to this selective IL-13 inhibitor for younger patients.
Ongoing Clinical Development
The ADorable clinical program extends beyond the Phase 3 trial. ADorable-2, a 52-week extension study of patients enrolled in ADorable-1, is ongoing and will provide critical long-term safety and efficacy data. Additional results from both ADorable trials are expected later in 2026.
Read More: AbbVie Reports Breakthrough Results for RINVOQ® (Upadacitinib) in Alopecia Areata Treatment
The Broader EBGLYSS Pipeline: Beyond Atopic Dermatitis
While the pediatric atopic dermatitis indication represents a major milestone, EBGLYSS development extends across multiple dermatological conditions. The comprehensive Phase 3 program in atopic dermatitis includes seven key global studies evaluating over 1,600 patients:
- ADvocate 1 and 2: Monotherapy studies.
- ADhere: Combination therapy with topical corticosteroids.
- ADjoin: Long-term extension study.
- ADore: Adolescent open-label study.
- ADorable 1 and 2: Pediatric studies.
Additionally, EBGLYSS is being investigated in other allergic conditions:
- Allergic rhinitis
- Chronic rhinosinusitis with nasal polyps
Novartis Fabhalta Iptacopan FDA Approval Becomes First Complement Inhibitor to Slow Kidney Decline in Primary IgAN
The FDA has granted traditional approval to Novartis' Fabhalta (iptacopan) — the first complement inhibitor shown to significantly slow kidney function decline in adults with […]
LIPFENDRA FDA Approval: Merck’s Enlicitide Becomes First Oral PCSK9 Inhibitor to Lower LDL-C
The LIPFENDRA FDA approval makes Merck's enlicitide the first once-daily oral PCSK9 inhibitor cleared to lower LDL-C in adults with hypercholesterolemia, including HeFH. Phase 3 […]
GSK Nuvalent Acquisition: GSK Completes $10.6 Billion Nuvalent Acquisition, Expanding Lung Cancer Pipeline
GSK has completed its $10.6 billion acquisition of Nuvalent, Inc., gaining three targeted lung cancer therapies, including zidesamtinib and neladalkib, both currently under FDA review […]
Current EBGLYSS Approvals and Availability
Global Regulatory Status
EBGLYSS has already received approval in multiple key markets:
- United States (2024)
- Japan (2024)
- Canada (2024)
- European Union (2023)
Currently, EBGLYSS is approved as a first-line biologic treatment with a monotherapy option for adults and children 12 years of age and older who weigh at least 88 pounds (40 kg) with moderate-to-severe atopic dermatitis inadequately controlled by topical prescription therapies.
Dosing and Administration
The current dosing regimen for EBGLYSS includes:
| Treatment Phase | Dosing Regimen | Frequency |
|---|---|---|
| Initial Phase | 500 mg (two 250 mg injections) | At Week 0 and Week 2 |
| Loading Phase | 250 mg per injection | Every two weeks until Week 16 or until adequate clinical response |
| Maintenance Phase | 250 mg per injection | Once monthly (every four weeks) |
Last Modified:
